Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)

Petr Ošťádal(Charles University), Jana Čepová(Charles University), Peter Telekes(Krajská Nemocnice Liberec), Petr Hájek(University Hospital in Motol), O Aschermann(Na Homolce Hospital), Jiří Kettner(Institute of Clinical and Experimental Medicine), Josef Veselka(Universitat Autònoma de Barcelona), Milan Maçek(Charles University), Jiří Kukačka(Charles University), David Hořák(Krajská Nemocnice Liberec), Peter Blaško, Milan Kvapil(Charles University), Martin Mates(Masaryk University), Jiří Vejvoda(University Hospital in Motol), Josef Slaby, David Alan(University Hospital in Motol), David Zemánek, F Holm(Technical University of Liberec), Martin Wiendl(Institute of Clinical and Experimental Medicine)
Trials
May 25, 2010
10.1186/1745-6215-11-61
Cited by 29

Related Papers

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest
|JAMA|2022|674
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis
|Nature Genetics|2007|440
The origin of the major cystic fibrosis mutation (ΔF508) in European populations
|Nature Genetics|1994|347
Variants in CPA1 are strongly associated with early onset chronic pancreatitis
|Nature Genetics|2013|305